trump and glp-1 President announced the popular weight loss drugs would soon be more accessible to millions of Americans at a cost of only $50 per month. | Fox 5 DC Eli Lilly and Novo Nordisk

With the weight-loss drug market surpassing $100 billion, legal and regulatory risks are intensifying

Conclusion GLP-1RAs show significant promise as a potential disease-modifying therapy for neurodegenerative and inflammatory eye diseases, acting through both systemic metabolic improvements and direct ocular mechanisms, representing a paradigm shift beyond their metabolic indications.

The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of Eli Lillys Zepbound.

No significant associations were observed for anorexia nervosa, broad depression, major depressive disorder (MDD), or suicide and intentional self-harm

A comprehensive review of the literature was conducted to examine the etiology of HFpEF, the role of endothelial dysfunction, and the effects of GLP-1R agonists on endothelial function and heart failure outcomes

Learn how GLP-1 medications like Semaglutide and Tirzepatide can aid in weight loss and improve overall health.